Dr. Flinn Discusses the DYNAMO Trial

Ian W. Flinn, MD, PhD
Published: Tuesday, Oct 14, 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Flinn says this phase II trial enrolled patients who were no longer responding to rituximab or chemotherapy. There is currently no established therapy for these patients.

In this trial, all patients will receive IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, as a single agent, Flinn says. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of blood cancers and inflammatory diseases.

The trial is ongoing and is currently accruing patients in the United States and the United Kingdom.  
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Flinn says this phase II trial enrolled patients who were no longer responding to rituximab or chemotherapy. There is currently no established therapy for these patients.

In this trial, all patients will receive IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, as a single agent, Flinn says. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of blood cancers and inflammatory diseases.

The trial is ongoing and is currently accruing patients in the United States and the United Kingdom.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x